Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-07-03-Speech-2-317-000"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20120703.18.2-317-000"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
"Against. The biggest criticisms we have: the scope is much too wide; for us it should be limited to real counterfeited trademarks and not cover other IPRs such as patents, plant variety, etc.; it is not up to the customs officials to enforce those rights, it is the responsibility of rights holders to proceed; goods in transit should not be concerned; developing countries have legitimate concerns regarding the interception of goods, in particular medicines, which are in transit and not intended for marketing in the EU: such interceptions interrupt the supply of generic medicines which these countries need; parallel trade should be allowed: it is allowed under the TRIPS agreement and therefore, there must be a derogation for parallel trade, in particular, because it can contribute to lowering the cost of medicines in developing countries."@en1
|
lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples